What were Tatva Chintan Pharma Chem Ltd's latest quarterly results?
Tatva Chintan Pharma Chem Ltd's latest quarterly results (Dec 2025) show
- Revenue Growth YoY: +52.3%
- Operating Margin: 19.0% (volatile)
Tatva Chintan Pharma Chem Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +19.5%Weak
In , Tatva Chintan Pharma Chem Ltd (Speciality Chemicals) is outperforming Nifty 500 with +19.5% relative strength. Fundamentals: Weak.
Tatva Chintan Pharma Chem Ltd Key Facts
- PE Ratio
- 96.5x
- Market Cap
- ₹3,163 Cr
- Revenue Growth YoY
- +52%
- OPM
- 19.0%
- RS vs Nifty 500
- +19.5%
PE: Near TroughRiding Wave
What's Happening
📊Debt increased 131% YoY — leverage rising
🏛️DII reducing — stake down 3.0%
Key Numbers
Revenue YoY
+52%
Accelerating
Operating Margin
19.0%
+1100 bps YoY
PE Ratio
96.5
Current Price
₹1,352
Dividend Yield
0.07%
Fundamental Score
39/100
Weak
3Y PAT CAGR
-50%
Market Cap
3.2K Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Tatva Chintan Pharma Chem Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +52% | -4% | Accelerating |
| OPM | 19.0% | +1100 bps | Volatile |
Other Top Speciality Chemicals Stocks Beating Nifty 500
Frequently Asked Questions: Tatva Chintan Pharma Chem Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Tatva Chintan Pharma Chem Ltd's profit growing or declining?
Tatva Chintan Pharma Chem Ltd's profit is declining with an turning around (inflection up) trend.
- PAT Growth QoQ: +50.0% (sequential)
- 3-Year PAT CAGR: -50.0%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Tatva Chintan Pharma Chem Ltd's revenue growth trend?
Tatva Chintan Pharma Chem Ltd's revenue growth trend is accelerating.
- Revenue Growth YoY: +52.3%
- Revenue Growth QoQ: +5.6% (sequential)
- 3-Year Revenue CAGR: -4.1%
How is Tatva Chintan Pharma Chem Ltd's operating margin trending?
Tatva Chintan Pharma Chem Ltd's operating margin is volatile.
- Current OPM: 19.0%
- OPM Change YoY: +11.0% basis points
- OPM Change QoQ: +1.0% basis points
What is Tatva Chintan Pharma Chem Ltd's 3-year profit and revenue CAGR?
Tatva Chintan Pharma Chem Ltd's long-term compounding rates
- 3-Year Profit CAGR: -50.0%
- 3-Year Revenue CAGR: -4.1%
Is Tatva Chintan Pharma Chem Ltd's growth accelerating or decelerating?
Tatva Chintan Pharma Chem Ltd's earnings growth is turning around (inflection up) with positive momentum on a sequential basis.
- Sequential Acceleration: +7.1% bps
What is Tatva Chintan Pharma Chem Ltd's trailing twelve month (TTM) performance?
Tatva Chintan Pharma Chem Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹33 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹480 Cr
- TTM Revenue Growth: +29.0% YoY
- TTM Operating Margin: 15.3%
What is Tatva Chintan Pharma Chem Ltd's current PE ratio?
Tatva Chintan Pharma Chem Ltd's current PE ratio is 96.5x.
- Current PE: 96.5x
- Market Cap: 3.2K Cr
- Dividend Yield: 0.07%
What is Tatva Chintan Pharma Chem Ltd's price-to-book ratio?
Tatva Chintan Pharma Chem Ltd's price-to-book ratio is 4.2x.
- Price-to-Book (P/B): 4.2x
- Book Value per Share: ₹322
- Current Price: ₹1352
Is Tatva Chintan Pharma Chem Ltd a fundamentally strong company?
Tatva Chintan Pharma Chem Ltd is rated Weak with a fundamental score of 38.75/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +52.3% (10% weight)
- PAT Growth QoQ: +50.0% (10% weight)
- Margins stable (10% weight)
Is Tatva Chintan Pharma Chem Ltd debt free?
Tatva Chintan Pharma Chem Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹83 Cr
What is Tatva Chintan Pharma Chem Ltd's return on equity (ROE) and ROCE?
Tatva Chintan Pharma Chem Ltd's return ratios over recent years
- FY2023: ROCE 9.0%
- FY2024: ROCE 7.0%
- FY2025: ROCE 1.0%
Is Tatva Chintan Pharma Chem Ltd's cash flow positive?
Tatva Chintan Pharma Chem Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹25 Cr
- Free Cash Flow (FCF): ₹-40 Cr
- CFO/PAT Ratio: 417% (strong cash conversion)
What is Tatva Chintan Pharma Chem Ltd's dividend yield?
Tatva Chintan Pharma Chem Ltd's current dividend yield is 0.07%.
- Dividend Yield: 0.07%
- Current Price: ₹1352
Who holds Tatva Chintan Pharma Chem Ltd shares — promoters, FII, DII?
Tatva Chintan Pharma Chem Ltd's shareholding pattern (Mar 2026)
- Promoters: 72.0%
- FII (Foreign): 3.8%
- DII (Domestic): 3.0%
- Public: 21.2%
Is promoter holding increasing or decreasing in Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 72.0% (Mar 2026)
- Previous Quarter: 72.0% (Dec 2025)
- Change: 0.00% (stable)
How long has Tatva Chintan Pharma Chem Ltd been outperforming Nifty 500?
Tatva Chintan Pharma Chem Ltd has been outperforming Nifty 500 for 2 consecutive weeks, indicating early-stage outperformance.
Is Tatva Chintan Pharma Chem Ltd a new momentum entry or an established outperformer?
Tatva Chintan Pharma Chem Ltd is an established outperformer with 2 weeks of consecutive Nifty 500 outperformance.
Is Tatva Chintan Pharma Chem Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Tatva Chintan Pharma Chem Ltd may be worth studying
- Revenue growth is accelerating — +52.3% YoY
- Cash flow is positive — CFO ₹25 Cr
What is the investment thesis for Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +52.3% YoY
What is the future outlook for Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: accelerating
- Margin Trend: volatile
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.